Revvity Inc

Latest Results (12.11.2025):

Revvity Inc reported robust financial results for the fourth quarter of 2024, marked by steady revenue growth and improved profitability metrics. The company achieved GAAP revenue of $729 million—up from $696 million a year ago—with GAAP EPS rising to $0.78 compared to $0.64, and adjusted EPS from continuing operations reaching $1.42 versus $1.25. Significant improvements were also noted in operating income and profit margins, alongside promising full-year 2025 guidance targeting revenue of $2.80–$2.85 billion and adjusted EPS of $4.90–$5.00.

Revenue Performance

For the fourth quarter of 2024, Revvity Inc recorded GAAP revenue of $729 million, reflecting a 5% reported growth and a 6% organic increase compared to the prior year. This steady revenue performance sets a strong foundation for continued momentum into 2025.

Earnings Improvement

The company’s financial results for Q4 2024 show improved profitability with GAAP EPS increasing to $0.78 from $0.64 and adjusted EPS rising to $1.42 from $1.25. Additionally, operating income from continuing operations increased from $77 million to $119 million, boosting the GAAP operating profit margin from 11.1% to 16.3%.

Segment Breakdown

Both key segments demonstrated growth in the fourth quarter. The Life Sciences segment delivered revenue of $336 million, achieving a 5% reported and organic growth, while the Diagnostics segment generated $393 million, with reported revenue up 4% and organic revenue growing 6% compared to the previous year.

Full-Year Guidance for 2025

Looking ahead, Revvity Inc has initiated full-year 2025 guidance, forecasting total revenue between $2.80 and $2.85 billion and non-GAAP adjusted EPS in the range of $4.90 to $5.00, underscoring management’s confidence in the ongoing transformation and solid performance momentum.